Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).
Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204). Tawbi, H., Forsyth, P. J., Hodi, F., Lao, C. D., Moschos, S. J., Hamid, O., Atkins, M. B., Lewis, K. D., Thomas, R., Glaspy, J. A., Jang, S., Algazi, A., Khushalani, N. I., Postow, M. A., Pavlick, A. C., Ernstoff, M. S., Reardon, D. A., Balogh, A., Rizzo, J. I., Margolin, K. AMER SOC CLINICAL ONCOLOGY. 2019View details for DOI 10.1200/JCO.2019.37.15_suppl.9501
View details for Web of Science ID 000487345806555